Equine rhinitis vaccine
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsPhillip Wayne HAYES, Kristina J. HENNESSY, Laurent VIEL, Andres DIAZ-MENDEZ
Life of this patent
Estimating the term…
Abstract
The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.
Claims57
An immunogenic composition comprising one or more strains of inactivated or live, attenuated Equine Rhinitis A Virus (ERAV) or Equine Rhinitis B Virus (ERBV), wherein the ERAV strain or the ERBV strain, prior to inactivation or attenuation, causes detectable respiratory disease in at least 50% of seronegative horses exposed to the strain, or grows in cell culture to 106 TCID50/mL or higher, or, when used as a vaccine in equines at a dose of 106 TCID50 or higher results in a serum titer of at least 1:112.
An immunogenic composition comprising an ERAV strain comprising a genomic sequence whose reverse transcript has greater than 95% identity to SEQ ID NO:
- 2 or encodes a polyprotein with an amino acid sequence with greater than 95% identity to SEQ ID NO:
- 3, wherein said ERAV strain, prior to inactivation or attenuation, is active to infect and replicate in host cells.
An immunogenic composition comprising an ERBV strain comprising a genomic sequence whose reverse transcript has greater than 95% identity to the reverse transcript of the genomic sequence of the ERBV strain having ATCC Accession no. PTA-11829 or encodes a polyprotein with an amino acid sequence with greater than 95% identity to the polyprotein encoded by the genome of the ERBV strain having ATCC Accession no. PTA-11829, wherein said ERBV strain, prior to inactivation or attenuation, is active to infect and replicate in host cells.
A method for producing an immunogenic composition comprising one or more strains of inactivated ERAV or ERBV, the method comprising:
- a) infecting a susceptible cell line with ERAV or ERBV;
- b) growing the infected cell line in growth media until a cytopathic effect (CPE) is attained;
- c) harvesting the media;
- d) filtering the media to yield a filtered media;
- and
- e) contacting the filtered media with an inactivating agent to obtain the inactivated ERAV or ERBV.
An immunogenic composition comprising ERAV/ON/05 and/or a ERBV strain having ATCC Accession NO:
- PTA-11829 and Amphotericin B, gentamicin sulfate, formaldehyde, and HRA-5.
Dependencies are inferred from the claim text.